How to Get Jatenzo in North Dakota

What Jatenzo Is and Why It Matters for North Dakota Patients

Jatenzo is the first FDA-approved oral testosterone undecanoate capsule for male hypogonadism, offering an alternative to injections, gels, and patches. The FDA granted approval in March 2019 based on a key trial showing that 87% of men achieved eugonadal testosterone levels (300 to 1 to 100 ng/dL) at the 237 mg twice-daily dose [1]. For men across North Dakota who prefer not to self-inject or deal with transdermal transfer risk, an oral option changes the daily treatment experience.

The Swerdloff et al. registration trial enrolled 166 hypogonadal men and measured average testosterone (Cavg) over 24 hours at steady state [1]. The 158 mg, 198 mg, and 237 mg twice-daily doses all restored testosterone into the normal range, with the 237 mg dose producing a mean Cavg of 489 ng/dL. Dose titration is built into the prescribing information: clinicians start at 237 mg twice daily, recheck levels after roughly one month, and adjust between 158 mg and 396 mg based on response [2].

Oral dosing does carry a distinct pharmacokinetic profile. Jatenzo relies on lymphatic absorption, which means it must be taken with a meal containing at least 15 to 20 grams of fat. Taking capsules on an empty stomach reduces bioavailability by approximately 40%, according to the FDA label [2]. North Dakota patients should plan their dosing around breakfast and dinner.

Telehealth Prescribing for Jatenzo in North Dakota

North Dakota law permits telehealth prescribing of Schedule III controlled substances, including testosterone, as long as the provider holds an active North Dakota medical license or practices under a valid interstate compact agreement. This means you do not need to drive hours across rural ND counties to see a specialist.

A telehealth consultation for testosterone replacement therapy (TRT) typically follows the same clinical workflow as an in-person visit. The provider reviews your symptoms, medical history, and lab work, then writes the prescription electronically to a pharmacy of your choice. The Endocrine Society's 2018 clinical practice guideline recommends confirming hypogonadism with two separate morning serum total testosterone measurements below 300 ng/dL before initiating therapy [3]. Telehealth providers in North Dakota are bound by these same diagnostic standards.

HealthRX operates a telehealth platform that connects North Dakota residents with licensed prescribers experienced in TRT. After completing intake labs, patients receive a clinical consultation, and if appropriate, a Jatenzo prescription sent directly to their selected pharmacy. The entire process, from lab order to prescription, can take as few as five business days.

Lab Requirements Before Starting Jatenzo in North Dakota

Before any prescriber in North Dakota writes a Jatenzo prescription, you will need baseline bloodwork. The Endocrine Society guideline specifies the minimum workup [3]:

• Two morning total testosterone levels drawn between 7:00 AM and 10:00 AM on separate days, both below 300 ng/dL
• Complete blood count (CBC) to establish a baseline hematocrit, since testosterone therapy raises red blood cell mass
• Lipid panel because Jatenzo's FDA label carries a warning about dose-dependent increases in blood pressure and changes in HDL cholesterol [2]
• PSA and digital rectal exam for men aged 40 and older, per AUA/Endocrine Society screening recommendations
• Hepatic function panel given the oral route of administration

Quest Diagnostics and Labcorp both operate draw sites in Fargo, Bismarck, Grand Forks, and Minot. Patients in more rural areas can use mobile phlebotomy services or hospital-affiliated labs. HealthRX provides lab orders that are accepted at major national lab networks across North Dakota.

Follow-up labs are equally important. The FDA label recommends rechecking testosterone levels approximately one month after initiation or dose change, and monitoring hematocrit at 3 months, 6 months, and annually thereafter [2]. A hematocrit above 54% warrants dose reduction or temporary discontinuation per the Endocrine Society guideline [3].

Who Can Prescribe Jatenzo in North Dakota

North Dakota's prescriptive authority rules allow multiple provider types to prescribe Schedule III controlled substances. MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) can all write a Jatenzo prescription, provided they hold an active DEA registration and a valid North Dakota license.

NPs in North Dakota have full practice authority after completing a supervised transition period, meaning they can prescribe Jatenzo independently once that transition is complete. PAs prescribe under a collaborative agreement with a supervising physician but are not required to obtain co-signatures for individual prescriptions. In practice, this means patients in underserved areas of western North Dakota can often access TRT through NPs or PAs at local clinics or via telehealth without waiting weeks for an endocrinologist appointment.

Endocrinologists and urologists are concentrated in Fargo, Bismarck, and Grand Forks. If you live in Williston, Dickinson, or smaller communities, telehealth or a primary care provider comfortable with TRT may be the most practical path.

Pharmacy Access and Filling Your Prescription in North Dakota

Jatenzo is a brand-name product with no AB-rated generic equivalent as of May 2026. Not every retail pharmacy stocks it on the shelf. Large chains like CVS, Walgreens, and Walmart in Bismarck, Fargo, and Grand Forks can typically order Jatenzo within one to two business days. Independent pharmacies may need slightly longer.

Specialty pharmacies are another option. Some patients find that specialty pharmacy mail-order services offer better pricing or manufacturer copay card support. Tolmar's copay assistance program can reduce out-of-pocket costs for commercially insured patients to as low as $0 per month, though eligibility requirements apply.

HealthRX North Dakota Pharmacy Decision Framework

Choosing the right pharmacy channel depends on three variables: your insurance formulary status, your location, and your urgency.

| Scenario | Recommended Channel | Typical Time to Fill | |---|---|---| | Commercial insurance with PA approved | Retail chain (CVS, Walgreens) | 1 to 3 days | | Commercial insurance, PA pending | Specialty pharmacy with benefits investigation | 5 to 10 days | | Cash pay or coupon | Specialty mail-order or GoodRx pricing at retail | 1 to 5 days | | Rural ND, no local chain | Mail-order specialty pharmacy | 3 to 7 days shipping | | 503A compounded oral TU desired | Licensed 503A pharmacy (verify ND Board approval) | 5 to 14 days |

North Dakota's Board of Pharmacy licenses 503A compounding pharmacies to prepare oral testosterone undecanoate formulations. These compounded versions are not FDA-approved and differ from brand Jatenzo in formulation and bioavailability. Patients choosing this route should discuss absorption differences with their provider. The FDA's guidance on 503A compounding outlines the regulatory framework governing these products [4].

Insurance Coverage and Prior Authorization in North Dakota

North Dakota Medicaid does not cover Jatenzo for male hypogonadism as of 2026. This means Medicaid beneficiaries will need to pursue alternatives: compounded testosterone, injectable testosterone cypionate or enanthate (which Medicaid typically does cover), or cash-pay pricing for brand Jatenzo.

Commercial insurers in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica, generally place Jatenzo on a specialty or non-preferred brand tier. Prior authorization is almost always required. The typical PA criteria include:

1. Documentation of two low morning testosterone levels (below 300 ng/dL)
2. A confirmed diagnosis of male hypogonadism (ICD-10 E29.1)
3. Evidence that the patient has tried or cannot use injectable testosterone (some plans require step therapy)
4. Prescriber attestation that the patient is not using testosterone for age-related decline alone, infertility treatment, or athletic performance

PA turnaround varies by insurer. Expect 3 to 7 business days for a standard request. Urgent or expedited reviews can return a decision within 72 hours. If denied, North Dakota law entitles patients to an external review through the North Dakota Insurance Department.

The American Urological Association's 2018 guideline on testosterone deficiency supports the use of oral testosterone undecanoate as a first-line option for men with confirmed hypogonadism who prefer non-injectable routes [5]. Citing this guideline in a PA appeal letter can strengthen the clinical justification.

Blood Pressure Monitoring: A Jatenzo-Specific Safety Consideration

The FDA label for Jatenzo includes a boxed warning about dose-dependent increases in blood pressure [2]. In the registration trial, systolic BP increased by a mean of 3 to 5 mmHg compared to baseline, and the effect was more pronounced at the 396 mg dose [1]. The Endocrine Society recommends blood pressure checks at each follow-up visit for patients on oral testosterone undecanoate [3].

North Dakota patients using telehealth should own a validated home blood pressure monitor. The American Heart Association recommends the oscillometric upper-arm cuff style and suggests measuring twice in the morning and twice in the evening for the first week after starting or adjusting a new medication [6]. Readings consistently above 130/80 mmHg warrant a conversation with your prescriber about dose adjustment or antihypertensive therapy.

This is especially relevant for North Dakota's population health profile. The CDC's Behavioral Risk Factor Surveillance System reports that approximately 33% of North Dakota adults have diagnosed hypertension [7]. Prescribers should screen carefully before starting Jatenzo in patients with pre-existing high blood pressure and may prefer a lower starting dose of 158 mg twice daily in borderline cases.

Transferring a Jatenzo Prescription to North Dakota

If you are relocating to North Dakota from another state, your existing Jatenzo prescription can be transferred. Because testosterone is a Schedule III controlled substance, the transfer process requires direct pharmacy-to-pharmacy communication. You cannot simply bring a paper prescription from an out-of-state provider.

Steps for a successful transfer:

1. Confirm your new North Dakota pharmacy can order Jatenzo
2. Ask your current pharmacy to initiate the transfer by contacting the new pharmacy directly
3. Ensure your prescriber is willing to be contacted for verification; some North Dakota pharmacies will call the original prescriber to confirm the prescription is active
4. If your prescriber is not licensed in North Dakota, you will need a new provider. Telehealth platforms like HealthRX can establish care quickly and write a new prescription based on your existing labs and treatment history

North Dakota does not impose additional state-specific restrictions on controlled substance transfers beyond federal DEA requirements. The process typically takes one to three business days once both pharmacies are in communication.

Timeline: From First Contact to First Dose

Patients often want to know how long the entire process takes. Here is a realistic timeline for a North Dakota resident starting from scratch:

• Days 1 to 2: Complete online intake, receive lab order
• Days 3 to 5: Draw labs at a local site; results typically return within 24 to 48 hours
• Days 5 to 7: Telehealth consultation with licensed provider; prescription sent electronically if clinically appropriate
• Days 7 to 14: Prior authorization (if insured) or direct pharmacy fill (if cash pay)
• Day 7 to 17: First dose in hand

Cash-pay patients can sometimes compress this timeline to under one week. Patients requiring prior authorization should plan for up to two and a half weeks.

Cardiovascular Considerations and Long-Term Monitoring

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was the first large randomized controlled trial to evaluate cardiovascular safety of testosterone replacement in men with hypogonadism and established or high risk for cardiovascular disease [8]. The trial found that transdermal testosterone did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.96 to 95% CI 0.78 to 1.17) over a mean follow-up of 33 months.

While TRAVERSE used transdermal testosterone (not oral), the results informed the broader clinical understanding of TRT cardiovascular safety. The FDA has not issued additional cardiovascular restrictions specific to Jatenzo beyond the existing blood pressure warning. North Dakota prescribers should still monitor lipids, hematocrit, and blood pressure at the intervals recommended in the Endocrine Society guideline [3]: 3 months, 6 months, then annually.

"Clinicians should measure hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit rises above 54%, stop testosterone until hematocrit decreases to a safe level." This recommendation from the Endocrine Society 2018 guideline applies to all testosterone formulations, including Jatenzo [3].

Dr. Shalender Bhasin, lead investigator of the TRAVERSE trial, stated: "These findings provide reassurance that testosterone therapy, when prescribed for men with true hypogonadism and monitored appropriately, does not carry the excess cardiovascular risk that earlier observational studies suggested" [8].

Jatenzo vs. Injectable Testosterone: A Quick Comparison for ND Patients

Many North Dakota patients considering Jatenzo are weighing it against injectable testosterone cypionate, the most commonly prescribed TRT formulation. A few key differences:

Convenience: Jatenzo is an oral capsule taken twice daily. No needles, no injection-site reactions, no weekly or biweekly injection schedule. For patients with needle aversion or those who travel frequently across North Dakota's vast geography, oral dosing is simpler.

Testosterone level stability: Injectable testosterone cypionate produces peak-and-trough fluctuations. Jatenzo produces more stable 24-hour testosterone levels. The Swerdloff trial showed a Cmax-to-Cmin ratio that was narrower with oral dosing than typically seen with weekly intramuscular injections [1].

Cost: Injectable testosterone cypionate is available as a generic and costs as little as $30 to $60 per month without insurance. Brand Jatenzo carries a wholesale acquisition cost exceeding $500 per month, though copay cards and insurance can reduce this significantly.

Blood pressure effect: Jatenzo's boxed warning about blood pressure increases does not apply to injectable formulations. Patients with poorly controlled hypertension may be better served by injectable TRT.

Compounding in North Dakota: 503A Oral Testosterone Undecanoate

North Dakota permits 503A pharmacies to compound oral testosterone undecanoate formulations. These are made pursuant to individual patient prescriptions and are not FDA-approved. The FDA's page on compounding provides the regulatory overview [4].

Compounded oral testosterone undecanoate may differ from brand Jatenzo in several ways: the lipid-based carrier, capsule composition, and dissolution profile can all vary by pharmacy. This means the dose-response relationship established in Jatenzo's clinical trials may not directly apply to compounded formulations. Patients should discuss this with their prescriber and plan for more frequent lab monitoring during the titration period.

Pricing for compounded oral testosterone undecanoate typically ranges from $60 to $150 per month, making it substantially less expensive than brand Jatenzo for cash-pay patients.